GLP-1 & Incretin Science

GLP-1 Agonists and Alcohol Use: The Trial Evidence

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

Three randomised controlled trials have tested semaglutide in alcohol use disorder. All reported reductions in craving or heavy drinking against placebo. All were small (48, 50 and 108 participants) and short, running 8 to 26 weeks, so they establish a signal rather than an effect size.

Key facts

Trial 1
48 participants, 9 weeks, weekly injection
Trial 2
50 participants, 8 weeks, oral semaglutide
Trial 3
108 participants, 26 weeks, plus CBT
Consistent finding
Reduced craving and heavy drinking days
Largest trial size
108, small by any standard
Approved for this use
No, in any jurisdiction
Key references
PMID 39937469, PMID 42522065

Why anyone looked

The observation came before the hypothesis. People taking GLP-1 agonists for weight or glucose reported drinking less without intending to, consistently enough that it became a research question rather than an anecdote. That is a weak starting point epistemically (self-report from people undergoing a major metabolic intervention is confounded in obvious ways), which is why randomised trials followed.

The three trials

Hendershot and colleagues reported in JAMA Psychiatry in April 2025 on 48 non-treatment-seeking adults given low-dose weekly semaglutide over nine weeks, finding reduced alcohol consumed in a laboratory self-administration procedure and reduced weekly craving. Schacht and colleagues reported in the American Journal of Psychiatry in July 2026 on 50 people with moderate-to-severe alcohol use disorder given oral semaglutide over eight weeks, finding fewer heavy drinking days, fewer drinks per drinking day and reduced craving. A third trial randomised 108 treatment-seeking patients with comorbid obesity to semaglutide or placebo alongside cognitive behavioural therapy for 26 weeks, again reporting fewer heavy drinking days.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What size and duration mean here

Forty-eight, fifty and one hundred and eight participants are small trials. For comparison, SELECT enrolled 17,604 to establish a cardiovascular outcome. Small trials can establish that an effect exists; they are poorly suited to estimating how large it is, and they are vulnerable to chance findings. Nine weeks, eight weeks and twenty-six weeks are also short relative to a chronic condition where relapse is measured over years.

The populations were not the same

This matters more than it looks. The first trial enrolled non-treatment-seeking participants, people not currently trying to stop drinking. That is a standard early-phase design but a very different group from people in treatment. The third enrolled treatment-seeking patients receiving cognitive behavioural therapy alongside the drug. A finding in one population does not transfer automatically to the other, and the third design cannot separate the drug's contribution from the therapy's beyond what the placebo arm captures.

What the meta-analysis adds

A systematic review and meta-analysis in eClinicalMedicine in December 2025 pooled effects of GLP-1 receptor agonists on alcohol consumption. Pooling small trials increases precision but cannot fix their common limitations. If every included trial is short and small, the pooled result is a more precise estimate of a short-term effect in small samples.

Regulatory position

No GLP-1 agonist is approved for alcohol use disorder in any jurisdiction. This is an active research question with a consistent early signal, not an established indication, and material supplied for laboratory research has no relationship to it whatsoever.

Frequently asked questions

Does semaglutide treat alcohol use disorder?

It is not approved for that use anywhere. Three small randomised trials report reductions in craving and heavy drinking, which establishes a signal rather than an established treatment.

How strong is the evidence?

Consistent in direction across three trials, but all were small (48, 50 and 108 participants) and short. Consistency across small studies is encouraging, not conclusive.

Why would a metabolic drug affect drinking?

GLP-1 receptors are expressed in brain regions involved in reward processing as well as in appetite regulation, which is the leading mechanistic hypothesis.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.